151 related articles for article (PubMed ID: 9589291)
1. Last chance therapies and managed care. Pluralism, fair procedures, and legitimacy.
Daniels N; Sabin JE
Hastings Cent Rep; 1998; 28(2):27-41. PubMed ID: 9589291
[TBL] [Abstract][Full Text] [Related]
2. Experimental medical treatments: who should decide coverage?
Collins JC
Spec Law Dig Health Care Law; 1998 Jan; (226):9-45. PubMed ID: 10176412
[No Abstract] [Full Text] [Related]
3. New approach to administrative medical decision-making: evidence-based medicine using high dose chemotherapy/bone marrow transplant for breast cancer.
Lucey C; Westphal JR
South Med J; 1998 Feb; 91(2):196-201. PubMed ID: 9496875
[TBL] [Abstract][Full Text] [Related]
4. Perspectives. Indefinite results in ABMT (autologous bone marrow transplantation) trials add to challenges for practice standards, quality assurance in cancer care.
Cunningham R
Med Health; 1999 Apr; 53(16):suppl 1-4. PubMed ID: 10387749
[No Abstract] [Full Text] [Related]
5. Variation in approval by insurance companies of coverage for autologous bone marrow transplantation for breast cancer.
Peters WP; Rogers MC
N Engl J Med; 1994 Feb; 330(7):473-7. PubMed ID: 8289855
[TBL] [Abstract][Full Text] [Related]
6. Current legal intervention regarding "experimental" treatments must be changed: an analysis of high doses of chemotherapy with autologous bone marrow transplantation for breast cancer patients.
Smayda E
J Law Health; 1998-1999; 13(2):257-80. PubMed ID: 10947396
[No Abstract] [Full Text] [Related]
7. Cancer coverage. Why are insurers paying for this "experimental" therapy?
Med Econ; 1996 Sep; 73(17):38. PubMed ID: 10161873
[No Abstract] [Full Text] [Related]
8. The evolution of managed care.
Cloutier M
Trends Health Care Law Ethics; 1995; 10(1-2):67-72. PubMed ID: 7655238
[No Abstract] [Full Text] [Related]
9. Ethical issues in the allocation and reimbursement of bone marrow transplantation.
Faber-Langendoen K
Leukemia; 1993 Jul; 7(7):1117-21. PubMed ID: 8321041
[TBL] [Abstract][Full Text] [Related]
10. Experimental medical treatments: who should decide coverage?
Collins JC
Seattle Univ Law Rev; 1997; 20(2):451-87. PubMed ID: 16528856
[No Abstract] [Full Text] [Related]
11. Limits to health care: fair procedures, democratic deliberation, and the legitimacy problem for insurers.
Daniels N; Sabin J
Philos Public Aff; 1997; 26(4):303-50. PubMed ID: 11660435
[No Abstract] [Full Text] [Related]
12. Evaluating promising new treatments for life-threatening disease: implications of the HDC/ABMT experience for treating breast cancer.
Edwards S
Find Brief; 2005 Jan; 8(1):1-3. PubMed ID: 15672527
[No Abstract] [Full Text] [Related]
13. Investigational treatments: coverage, controversy, and consensus.
Ader M
Ann Health Law; 1996; (5):45-60. PubMed ID: 10164521
[No Abstract] [Full Text] [Related]
14. ABMT (autologous bone marrow transplantation): a microcosm of the U.S. health care system.
McGivney WT
Physician Exec; 1992; 18(1):45-7. PubMed ID: 10116423
[TBL] [Abstract][Full Text] [Related]
15. Last chance therapies: can a just and caring society do health care rationing when life itself is at stake?
Fleck LM
Yale J Health Policy Law Ethics; 2002; 2(2):255-98. PubMed ID: 12669315
[No Abstract] [Full Text] [Related]
16. Role of technology assessment in health benefits coverage for medical devices.
Braslow NM; Shatin D; McCarthy DB; Newcomer LN
Am J Manag Care; 1998 Sep; 4 Spec No():SP139-50. PubMed ID: 10185990
[TBL] [Abstract][Full Text] [Related]
17. Paying physicians more to do less: financial incentives to limit care.
Orentlicher D
Univ Richmond Law Rev; 1996 Jan; 30(1):155-97. PubMed ID: 11656852
[No Abstract] [Full Text] [Related]
18. Variations in insurance coverage for autologous bone marrow transplantation for breast cancer.
Cutler CM; Udvarhelyi IS; Winkenwerder W
N Engl J Med; 1994 Aug; 331(5):329-30. PubMed ID: 8022449
[No Abstract] [Full Text] [Related]
19. Framework for the selection of subjects in human gene therapy and diagnostic trials.
Modell SM
J Investig Med; 1996 Jun; 44(5):228-37. PubMed ID: 8763973
[No Abstract] [Full Text] [Related]
20. Mandates for unproven health care interventions.
Gervais KG; Priester R
Minn Med; 1996 Apr; 79(4):52-5. PubMed ID: 8637495
[No Abstract] [Full Text] [Related]
[Next] [New Search]
